nodes	percent_of_prediction	percent_of_DWPC	metapath
Dihydroergotamine—HTR1B—obesity	0.325	1	CbGaD
Dihydroergotamine—ADRA2A—Benzphetamine—obesity	0.0971	0.249	CbGbCtD
Dihydroergotamine—ADRA2A—Phenylpropanolamine—obesity	0.0926	0.238	CbGbCtD
Dihydroergotamine—ADRA2A—Methamphetamine—obesity	0.0776	0.199	CbGbCtD
Dihydroergotamine—CYP3A4—Sibutramine—obesity	0.0271	0.0696	CbGbCtD
Dihydroergotamine—ABCB1—Cimetidine—obesity	0.0214	0.0549	CbGbCtD
Dihydroergotamine—CYP3A4—Benzphetamine—obesity	0.0205	0.0528	CbGbCtD
Dihydroergotamine—CYP3A4—Bupropion—obesity	0.0175	0.0449	CbGbCtD
Dihydroergotamine—CYP3A4—Orlistat—obesity	0.0142	0.0366	CbGbCtD
Dihydroergotamine—CYP3A4—Cimetidine—obesity	0.0128	0.0329	CbGbCtD
Dihydroergotamine—CYP3A4—Topiramate—obesity	0.00839	0.0215	CbGbCtD
Dihydroergotamine—Ergoloid mesylate—DRD1—obesity	0.000925	0.189	CrCbGaD
Dihydroergotamine—Ergoloid mesylate—DRD2—obesity	0.000652	0.133	CrCbGaD
Dihydroergotamine—Bromocriptine—DRD4—obesity	0.000412	0.084	CrCbGaD
Dihydroergotamine—Ergotamine—HTR1B—obesity	0.000379	0.0774	CrCbGaD
Dihydroergotamine—Bromocriptine—HTR1B—obesity	0.000366	0.0746	CrCbGaD
Dihydroergotamine—Bromocriptine—DRD1—obesity	0.000348	0.0711	CrCbGaD
Dihydroergotamine—Bromocriptine—ADRB1—obesity	0.000323	0.066	CrCbGaD
Dihydroergotamine—Ergotamine—HTR2C—obesity	0.000309	0.0631	CrCbGaD
Dihydroergotamine—Bromocriptine—HTR2C—obesity	0.000298	0.0608	CrCbGaD
Dihydroergotamine—Sweating increased—Bupropion—obesity	0.000296	0.00187	CcSEcCtD
Dihydroergotamine—Rash—Phenylpropanolamine—obesity	0.000296	0.00186	CcSEcCtD
Dihydroergotamine—Dermatitis—Phenylpropanolamine—obesity	0.000295	0.00186	CcSEcCtD
Dihydroergotamine—Body temperature increased—Cimetidine—obesity	0.000294	0.00185	CcSEcCtD
Dihydroergotamine—Epistaxis—Sibutramine—obesity	0.000294	0.00185	CcSEcCtD
Dihydroergotamine—Bronchitis—Bupropion—obesity	0.000293	0.00184	CcSEcCtD
Dihydroergotamine—Sinusitis—Sibutramine—obesity	0.000292	0.00184	CcSEcCtD
Dihydroergotamine—Vaginal infection—Topiramate—obesity	0.000292	0.00184	CcSEcCtD
Dihydroergotamine—Photophobia—Topiramate—obesity	0.00029	0.00183	CcSEcCtD
Dihydroergotamine—Pharyngitis—Orlistat—obesity	0.000287	0.0018	CcSEcCtD
Dihydroergotamine—Vomiting—Phentermine—obesity	0.000285	0.0018	CcSEcCtD
Dihydroergotamine—Rash—Phentermine—obesity	0.000283	0.00178	CcSEcCtD
Dihydroergotamine—Upper respiratory tract infection—Bupropion—obesity	0.000283	0.00178	CcSEcCtD
Dihydroergotamine—Dermatitis—Phentermine—obesity	0.000283	0.00178	CcSEcCtD
Dihydroergotamine—Headache—Phentermine—obesity	0.000281	0.00177	CcSEcCtD
Dihydroergotamine—Pollakiuria—Bupropion—obesity	0.000281	0.00177	CcSEcCtD
Dihydroergotamine—Rhinitis—Sibutramine—obesity	0.00028	0.00176	CcSEcCtD
Dihydroergotamine—Bladder pain—Topiramate—obesity	0.000279	0.00176	CcSEcCtD
Dihydroergotamine—Nausea—Phenylpropanolamine—obesity	0.000279	0.00175	CcSEcCtD
Dihydroergotamine—Hypoaesthesia—Sibutramine—obesity	0.000278	0.00175	CcSEcCtD
Dihydroergotamine—Pharyngitis—Sibutramine—obesity	0.000277	0.00175	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Cimetidine—obesity	0.000274	0.00172	CcSEcCtD
Dihydroergotamine—Abnormal vision—Topiramate—obesity	0.00027	0.0017	CcSEcCtD
Dihydroergotamine—Hyperkinesia—Topiramate—obesity	0.00027	0.0017	CcSEcCtD
Dihydroergotamine—Visual impairment—Sibutramine—obesity	0.000269	0.00169	CcSEcCtD
Dihydroergotamine—Mental disability—Topiramate—obesity	0.000268	0.00169	CcSEcCtD
Dihydroergotamine—Acute coronary syndrome—Bupropion—obesity	0.000267	0.00168	CcSEcCtD
Dihydroergotamine—Diarrhoea—Diethylpropion—obesity	0.000267	0.00168	CcSEcCtD
Dihydroergotamine—Nausea—Phentermine—obesity	0.000267	0.00168	CcSEcCtD
Dihydroergotamine—Asthenia—Cimetidine—obesity	0.000267	0.00168	CcSEcCtD
Dihydroergotamine—Myocardial infarction—Bupropion—obesity	0.000266	0.00167	CcSEcCtD
Dihydroergotamine—Euphoric mood—Topiramate—obesity	0.000266	0.00167	CcSEcCtD
Dihydroergotamine—Conjunctivitis—Bupropion—obesity	0.000264	0.00166	CcSEcCtD
Dihydroergotamine—Ear pain—Topiramate—obesity	0.000263	0.00165	CcSEcCtD
Dihydroergotamine—Tinnitus—Sibutramine—obesity	0.00026	0.00164	CcSEcCtD
Dihydroergotamine—Dizziness—Diethylpropion—obesity	0.000258	0.00162	CcSEcCtD
Dihydroergotamine—Epistaxis—Bupropion—obesity	0.000256	0.00161	CcSEcCtD
Dihydroergotamine—Ergotamine—DRD2—obesity	0.000255	0.052	CrCbGaD
Dihydroergotamine—Sinusitis—Bupropion—obesity	0.000255	0.0016	CcSEcCtD
Dihydroergotamine—Diarrhoea—Cimetidine—obesity	0.000254	0.0016	CcSEcCtD
Dihydroergotamine—Chills—Sibutramine—obesity	0.000251	0.00158	CcSEcCtD
Dihydroergotamine—Eye pain—Topiramate—obesity	0.000248	0.00156	CcSEcCtD
Dihydroergotamine—Vomiting—Diethylpropion—obesity	0.000248	0.00156	CcSEcCtD
Dihydroergotamine—Rash—Diethylpropion—obesity	0.000246	0.00155	CcSEcCtD
Dihydroergotamine—Dermatitis—Diethylpropion—obesity	0.000246	0.00155	CcSEcCtD
Dihydroergotamine—Dizziness—Cimetidine—obesity	0.000246	0.00155	CcSEcCtD
Dihydroergotamine—Bromocriptine—DRD2—obesity	0.000246	0.0501	CrCbGaD
Dihydroergotamine—Headache—Diethylpropion—obesity	0.000245	0.00154	CcSEcCtD
Dihydroergotamine—Rhinitis—Bupropion—obesity	0.000244	0.00154	CcSEcCtD
Dihydroergotamine—Hypoaesthesia—Bupropion—obesity	0.000242	0.00153	CcSEcCtD
Dihydroergotamine—Pharyngitis—Bupropion—obesity	0.000242	0.00152	CcSEcCtD
Dihydroergotamine—Muscle spasms—Orlistat—obesity	0.000242	0.00152	CcSEcCtD
Dihydroergotamine—Hot flush—Topiramate—obesity	0.00024	0.00151	CcSEcCtD
Dihydroergotamine—Tension—Sibutramine—obesity	0.000239	0.0015	CcSEcCtD
Dihydroergotamine—Menopausal symptoms—Topiramate—obesity	0.000238	0.0015	CcSEcCtD
Dihydroergotamine—Nervousness—Sibutramine—obesity	0.000236	0.00149	CcSEcCtD
Dihydroergotamine—Vomiting—Cimetidine—obesity	0.000236	0.00149	CcSEcCtD
Dihydroergotamine—Visual impairment—Bupropion—obesity	0.000235	0.00148	CcSEcCtD
Dihydroergotamine—Rash—Cimetidine—obesity	0.000234	0.00147	CcSEcCtD
Dihydroergotamine—Dermatitis—Cimetidine—obesity	0.000234	0.00147	CcSEcCtD
Dihydroergotamine—Muscle spasms—Sibutramine—obesity	0.000234	0.00147	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Orlistat—obesity	0.000233	0.00147	CcSEcCtD
Dihydroergotamine—Headache—Cimetidine—obesity	0.000233	0.00146	CcSEcCtD
Dihydroergotamine—Nausea—Diethylpropion—obesity	0.000232	0.00146	CcSEcCtD
Dihydroergotamine—Tremor—Sibutramine—obesity	0.000228	0.00143	CcSEcCtD
Dihydroergotamine—Tinnitus—Bupropion—obesity	0.000227	0.00143	CcSEcCtD
Dihydroergotamine—Malaise—Orlistat—obesity	0.000227	0.00143	CcSEcCtD
Dihydroergotamine—Flushing—Bupropion—obesity	0.000226	0.00142	CcSEcCtD
Dihydroergotamine—Vertigo—Orlistat—obesity	0.000226	0.00142	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Sibutramine—obesity	0.000226	0.00142	CcSEcCtD
Dihydroergotamine—Agitation—Sibutramine—obesity	0.000224	0.00141	CcSEcCtD
Dihydroergotamine—Palpitations—Orlistat—obesity	0.000222	0.0014	CcSEcCtD
Dihydroergotamine—Migraine—Topiramate—obesity	0.000221	0.00139	CcSEcCtD
Dihydroergotamine—Nausea—Cimetidine—obesity	0.000221	0.00139	CcSEcCtD
Dihydroergotamine—Malaise—Sibutramine—obesity	0.000219	0.00138	CcSEcCtD
Dihydroergotamine—Chills—Bupropion—obesity	0.000219	0.00138	CcSEcCtD
Dihydroergotamine—Vertigo—Sibutramine—obesity	0.000219	0.00138	CcSEcCtD
Dihydroergotamine—Face oedema—Topiramate—obesity	0.000217	0.00136	CcSEcCtD
Dihydroergotamine—Palpitations—Sibutramine—obesity	0.000215	0.00135	CcSEcCtD
Dihydroergotamine—Myalgia—Orlistat—obesity	0.000214	0.00135	CcSEcCtD
Dihydroergotamine—Anxiety—Orlistat—obesity	0.000213	0.00134	CcSEcCtD
Dihydroergotamine—Discomfort—Orlistat—obesity	0.000211	0.00133	CcSEcCtD
Dihydroergotamine—Hypertension—Sibutramine—obesity	0.00021	0.00132	CcSEcCtD
Dihydroergotamine—Dry mouth—Orlistat—obesity	0.000209	0.00132	CcSEcCtD
Dihydroergotamine—Tension—Bupropion—obesity	0.000208	0.00131	CcSEcCtD
Dihydroergotamine—Myalgia—Sibutramine—obesity	0.000207	0.0013	CcSEcCtD
Dihydroergotamine—Arthralgia—Sibutramine—obesity	0.000207	0.0013	CcSEcCtD
Dihydroergotamine—Anxiety—Sibutramine—obesity	0.000206	0.0013	CcSEcCtD
Dihydroergotamine—Nervousness—Bupropion—obesity	0.000206	0.0013	CcSEcCtD
Dihydroergotamine—Oedema—Orlistat—obesity	0.000205	0.00129	CcSEcCtD
Dihydroergotamine—Discomfort—Sibutramine—obesity	0.000205	0.00129	CcSEcCtD
Dihydroergotamine—Muscle spasms—Bupropion—obesity	0.000204	0.00128	CcSEcCtD
Dihydroergotamine—Dry mouth—Sibutramine—obesity	0.000203	0.00127	CcSEcCtD
Dihydroergotamine—Confusional state—Sibutramine—obesity	0.0002	0.00126	CcSEcCtD
Dihydroergotamine—Tremor—Bupropion—obesity	0.000199	0.00125	CcSEcCtD
Dihydroergotamine—Oedema—Sibutramine—obesity	0.000198	0.00125	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Orlistat—obesity	0.000198	0.00125	CcSEcCtD
Dihydroergotamine—Muscular weakness—Topiramate—obesity	0.000198	0.00125	CcSEcCtD
Dihydroergotamine—Ergotamine—HTR2A—obesity	0.000197	0.0402	CrCbGaD
Dihydroergotamine—Ill-defined disorder—Bupropion—obesity	0.000197	0.00124	CcSEcCtD
Dihydroergotamine—Shock—Sibutramine—obesity	0.000195	0.00123	CcSEcCtD
Dihydroergotamine—Agitation—Bupropion—obesity	0.000195	0.00123	CcSEcCtD
Dihydroergotamine—Dysphagia—Topiramate—obesity	0.000194	0.00122	CcSEcCtD
Dihydroergotamine—Tachycardia—Sibutramine—obesity	0.000194	0.00122	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Sibutramine—obesity	0.000192	0.00121	CcSEcCtD
Dihydroergotamine—Malaise—Bupropion—obesity	0.000191	0.0012	CcSEcCtD
Dihydroergotamine—Vertigo—Bupropion—obesity	0.000191	0.0012	CcSEcCtD
Dihydroergotamine—Bromocriptine—HTR2A—obesity	0.00019	0.0387	CrCbGaD
Dihydroergotamine—Anorexia—Sibutramine—obesity	0.000189	0.00119	CcSEcCtD
Dihydroergotamine—Angina pectoris—Topiramate—obesity	0.000189	0.00119	CcSEcCtD
Dihydroergotamine—Sweating increased—Topiramate—obesity	0.000189	0.00119	CcSEcCtD
Dihydroergotamine—Palpitations—Bupropion—obesity	0.000187	0.00118	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Orlistat—obesity	0.000187	0.00118	CcSEcCtD
Dihydroergotamine—Bronchitis—Topiramate—obesity	0.000186	0.00117	CcSEcCtD
Dihydroergotamine—Insomnia—Orlistat—obesity	0.000186	0.00117	CcSEcCtD
Dihydroergotamine—Hypotension—Sibutramine—obesity	0.000185	0.00117	CcSEcCtD
Dihydroergotamine—Paraesthesia—Orlistat—obesity	0.000184	0.00116	CcSEcCtD
Dihydroergotamine—Hypertension—Bupropion—obesity	0.000183	0.00115	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Sibutramine—obesity	0.000181	0.00114	CcSEcCtD
Dihydroergotamine—Dyspepsia—Orlistat—obesity	0.000181	0.00114	CcSEcCtD
Dihydroergotamine—Myalgia—Bupropion—obesity	0.000181	0.00114	CcSEcCtD
Dihydroergotamine—Arthralgia—Bupropion—obesity	0.000181	0.00114	CcSEcCtD
Dihydroergotamine—Upper respiratory tract infection—Topiramate—obesity	0.00018	0.00113	CcSEcCtD
Dihydroergotamine—Anxiety—Bupropion—obesity	0.00018	0.00113	CcSEcCtD
Dihydroergotamine—Insomnia—Sibutramine—obesity	0.00018	0.00113	CcSEcCtD
Dihydroergotamine—Pollakiuria—Topiramate—obesity	0.000179	0.00113	CcSEcCtD
Dihydroergotamine—Discomfort—Bupropion—obesity	0.000178	0.00112	CcSEcCtD
Dihydroergotamine—Decreased appetite—Orlistat—obesity	0.000178	0.00112	CcSEcCtD
Dihydroergotamine—Paraesthesia—Sibutramine—obesity	0.000178	0.00112	CcSEcCtD
Dihydroergotamine—Dyspnoea—Sibutramine—obesity	0.000177	0.00111	CcSEcCtD
Dihydroergotamine—Fatigue—Orlistat—obesity	0.000177	0.00111	CcSEcCtD
Dihydroergotamine—Dry mouth—Bupropion—obesity	0.000177	0.00111	CcSEcCtD
Dihydroergotamine—Somnolence—Sibutramine—obesity	0.000176	0.00111	CcSEcCtD
Dihydroergotamine—Pain—Orlistat—obesity	0.000175	0.0011	CcSEcCtD
Dihydroergotamine—Dyspepsia—Sibutramine—obesity	0.000175	0.0011	CcSEcCtD
Dihydroergotamine—Confusional state—Bupropion—obesity	0.000174	0.0011	CcSEcCtD
Dihydroergotamine—Oedema—Bupropion—obesity	0.000173	0.00109	CcSEcCtD
Dihydroergotamine—Decreased appetite—Sibutramine—obesity	0.000173	0.00109	CcSEcCtD
Dihydroergotamine—Shock—Bupropion—obesity	0.00017	0.00107	CcSEcCtD
Dihydroergotamine—Pain—Sibutramine—obesity	0.00017	0.00107	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Orlistat—obesity	0.000169	0.00106	CcSEcCtD
Dihydroergotamine—Tachycardia—Bupropion—obesity	0.000169	0.00106	CcSEcCtD
Dihydroergotamine—Conjunctivitis—Topiramate—obesity	0.000168	0.00106	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Orlistat—obesity	0.000168	0.00106	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Bupropion—obesity	0.000167	0.00105	CcSEcCtD
Dihydroergotamine—Anorexia—Bupropion—obesity	0.000165	0.00104	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Sibutramine—obesity	0.000164	0.00103	CcSEcCtD
Dihydroergotamine—Epistaxis—Topiramate—obesity	0.000163	0.00103	CcSEcCtD
Dihydroergotamine—Urticaria—Orlistat—obesity	0.000163	0.00103	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Sibutramine—obesity	0.000162	0.00102	CcSEcCtD
Dihydroergotamine—Sinusitis—Topiramate—obesity	0.000162	0.00102	CcSEcCtD
Dihydroergotamine—Abdominal pain—Orlistat—obesity	0.000162	0.00102	CcSEcCtD
Dihydroergotamine—Body temperature increased—Orlistat—obesity	0.000162	0.00102	CcSEcCtD
Dihydroergotamine—Hypotension—Bupropion—obesity	0.000162	0.00102	CcSEcCtD
Dihydroergotamine—Urticaria—Sibutramine—obesity	0.000158	0.000992	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Bupropion—obesity	0.000158	0.000992	CcSEcCtD
Dihydroergotamine—Abdominal pain—Sibutramine—obesity	0.000157	0.000987	CcSEcCtD
Dihydroergotamine—Body temperature increased—Sibutramine—obesity	0.000157	0.000987	CcSEcCtD
Dihydroergotamine—Insomnia—Bupropion—obesity	0.000157	0.000985	CcSEcCtD
Dihydroergotamine—Rhinitis—Topiramate—obesity	0.000156	0.000979	CcSEcCtD
Dihydroergotamine—Paraesthesia—Bupropion—obesity	0.000155	0.000978	CcSEcCtD
Dihydroergotamine—Hypoaesthesia—Topiramate—obesity	0.000154	0.000972	CcSEcCtD
Dihydroergotamine—Dyspnoea—Bupropion—obesity	0.000154	0.000971	CcSEcCtD
Dihydroergotamine—Pharyngitis—Topiramate—obesity	0.000154	0.000969	CcSEcCtD
Dihydroergotamine—Somnolence—Bupropion—obesity	0.000154	0.000968	CcSEcCtD
Dihydroergotamine—Dyspepsia—Bupropion—obesity	0.000152	0.000959	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Orlistat—obesity	0.000151	0.000951	CcSEcCtD
Dihydroergotamine—Decreased appetite—Bupropion—obesity	0.00015	0.000947	CcSEcCtD
Dihydroergotamine—Visual impairment—Topiramate—obesity	0.00015	0.000941	CcSEcCtD
Dihydroergotamine—Fatigue—Bupropion—obesity	0.000149	0.000939	CcSEcCtD
Dihydroergotamine—Pain—Bupropion—obesity	0.000148	0.000931	CcSEcCtD
Dihydroergotamine—Asthenia—Orlistat—obesity	0.000147	0.000926	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Sibutramine—obesity	0.000146	0.00092	CcSEcCtD
Dihydroergotamine—Pruritus—Orlistat—obesity	0.000145	0.000913	CcSEcCtD
Dihydroergotamine—Tinnitus—Topiramate—obesity	0.000145	0.000911	CcSEcCtD
Dihydroergotamine—Flushing—Topiramate—obesity	0.000144	0.000906	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Bupropion—obesity	0.000143	0.000897	CcSEcCtD
Dihydroergotamine—Asthenia—Sibutramine—obesity	0.000142	0.000896	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Bupropion—obesity	0.000142	0.00089	CcSEcCtD
Dihydroergotamine—Pruritus—Sibutramine—obesity	0.00014	0.000884	CcSEcCtD
Dihydroergotamine—Diarrhoea—Orlistat—obesity	0.00014	0.000883	CcSEcCtD
Dihydroergotamine—Chills—Topiramate—obesity	0.000139	0.000876	CcSEcCtD
Dihydroergotamine—Urticaria—Bupropion—obesity	0.000137	0.000865	CcSEcCtD
Dihydroergotamine—Abdominal pain—Bupropion—obesity	0.000137	0.000861	CcSEcCtD
Dihydroergotamine—Body temperature increased—Bupropion—obesity	0.000137	0.000861	CcSEcCtD
Dihydroergotamine—Diarrhoea—Sibutramine—obesity	0.000136	0.000855	CcSEcCtD
Dihydroergotamine—Dizziness—Orlistat—obesity	0.000136	0.000854	CcSEcCtD
Dihydroergotamine—Tension—Topiramate—obesity	0.000133	0.000834	CcSEcCtD
Dihydroergotamine—Dizziness—Sibutramine—obesity	0.000131	0.000826	CcSEcCtD
Dihydroergotamine—Nervousness—Topiramate—obesity	0.000131	0.000826	CcSEcCtD
Dihydroergotamine—Vomiting—Orlistat—obesity	0.00013	0.000821	CcSEcCtD
Dihydroergotamine—Muscle spasms—Topiramate—obesity	0.00013	0.000817	CcSEcCtD
Dihydroergotamine—Rash—Orlistat—obesity	0.000129	0.000814	CcSEcCtD
Dihydroergotamine—Dermatitis—Orlistat—obesity	0.000129	0.000813	CcSEcCtD
Dihydroergotamine—Headache—Orlistat—obesity	0.000128	0.000809	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Bupropion—obesity	0.000127	0.000802	CcSEcCtD
Dihydroergotamine—Tremor—Topiramate—obesity	0.000127	0.000796	CcSEcCtD
Dihydroergotamine—Vomiting—Sibutramine—obesity	0.000126	0.000794	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Topiramate—obesity	0.000125	0.000789	CcSEcCtD
Dihydroergotamine—Rash—Sibutramine—obesity	0.000125	0.000788	CcSEcCtD
Dihydroergotamine—Dermatitis—Sibutramine—obesity	0.000125	0.000787	CcSEcCtD
Dihydroergotamine—Headache—Sibutramine—obesity	0.000124	0.000783	CcSEcCtD
Dihydroergotamine—Asthenia—Bupropion—obesity	0.000124	0.000781	CcSEcCtD
Dihydroergotamine—Agitation—Topiramate—obesity	0.000124	0.000781	CcSEcCtD
Dihydroergotamine—Pruritus—Bupropion—obesity	0.000122	0.00077	CcSEcCtD
Dihydroergotamine—Nausea—Orlistat—obesity	0.000122	0.000767	CcSEcCtD
Dihydroergotamine—Malaise—Topiramate—obesity	0.000122	0.000767	CcSEcCtD
Dihydroergotamine—Vertigo—Topiramate—obesity	0.000121	0.000764	CcSEcCtD
Dihydroergotamine—Palpitations—Topiramate—obesity	0.000119	0.000751	CcSEcCtD
Dihydroergotamine—Diarrhoea—Bupropion—obesity	0.000118	0.000745	CcSEcCtD
Dihydroergotamine—Nausea—Sibutramine—obesity	0.000118	0.000742	CcSEcCtD
Dihydroergotamine—Hypertension—Topiramate—obesity	0.000117	0.000734	CcSEcCtD
Dihydroergotamine—Myalgia—Topiramate—obesity	0.000115	0.000724	CcSEcCtD
Dihydroergotamine—Arthralgia—Topiramate—obesity	0.000115	0.000724	CcSEcCtD
Dihydroergotamine—Anxiety—Topiramate—obesity	0.000115	0.000721	CcSEcCtD
Dihydroergotamine—Dizziness—Bupropion—obesity	0.000114	0.00072	CcSEcCtD
Dihydroergotamine—Discomfort—Topiramate—obesity	0.000114	0.000715	CcSEcCtD
Dihydroergotamine—Dry mouth—Topiramate—obesity	0.000112	0.000708	CcSEcCtD
Dihydroergotamine—Confusional state—Topiramate—obesity	0.000111	0.0007	CcSEcCtD
Dihydroergotamine—Oedema—Topiramate—obesity	0.00011	0.000694	CcSEcCtD
Dihydroergotamine—Vomiting—Bupropion—obesity	0.00011	0.000692	CcSEcCtD
Dihydroergotamine—Rash—Bupropion—obesity	0.000109	0.000687	CcSEcCtD
Dihydroergotamine—Dermatitis—Bupropion—obesity	0.000109	0.000686	CcSEcCtD
Dihydroergotamine—Shock—Topiramate—obesity	0.000108	0.000683	CcSEcCtD
Dihydroergotamine—Headache—Bupropion—obesity	0.000108	0.000682	CcSEcCtD
Dihydroergotamine—Tachycardia—Topiramate—obesity	0.000108	0.000677	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Topiramate—obesity	0.000107	0.000671	CcSEcCtD
Dihydroergotamine—Anorexia—Topiramate—obesity	0.000105	0.000661	CcSEcCtD
Dihydroergotamine—Hypotension—Topiramate—obesity	0.000103	0.000648	CcSEcCtD
Dihydroergotamine—Nausea—Bupropion—obesity	0.000103	0.000647	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Topiramate—obesity	0.0001	0.000632	CcSEcCtD
Dihydroergotamine—Insomnia—Topiramate—obesity	9.97e-05	0.000628	CcSEcCtD
Dihydroergotamine—Paraesthesia—Topiramate—obesity	9.9e-05	0.000623	CcSEcCtD
Dihydroergotamine—Dyspnoea—Topiramate—obesity	9.83e-05	0.000619	CcSEcCtD
Dihydroergotamine—Somnolence—Topiramate—obesity	9.8e-05	0.000617	CcSEcCtD
Dihydroergotamine—Dyspepsia—Topiramate—obesity	9.7e-05	0.000611	CcSEcCtD
Dihydroergotamine—Decreased appetite—Topiramate—obesity	9.58e-05	0.000603	CcSEcCtD
Dihydroergotamine—Fatigue—Topiramate—obesity	9.51e-05	0.000598	CcSEcCtD
Dihydroergotamine—Pain—Topiramate—obesity	9.43e-05	0.000593	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Topiramate—obesity	9.09e-05	0.000572	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Topiramate—obesity	9.02e-05	0.000567	CcSEcCtD
Dihydroergotamine—Urticaria—Topiramate—obesity	8.76e-05	0.000551	CcSEcCtD
Dihydroergotamine—Abdominal pain—Topiramate—obesity	8.72e-05	0.000548	CcSEcCtD
Dihydroergotamine—Body temperature increased—Topiramate—obesity	8.72e-05	0.000548	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Topiramate—obesity	8.12e-05	0.000511	CcSEcCtD
Dihydroergotamine—Asthenia—Topiramate—obesity	7.91e-05	0.000498	CcSEcCtD
Dihydroergotamine—Pruritus—Topiramate—obesity	7.8e-05	0.000491	CcSEcCtD
Dihydroergotamine—Diarrhoea—Topiramate—obesity	7.54e-05	0.000475	CcSEcCtD
Dihydroergotamine—Dizziness—Topiramate—obesity	7.29e-05	0.000459	CcSEcCtD
Dihydroergotamine—Vomiting—Topiramate—obesity	7.01e-05	0.000441	CcSEcCtD
Dihydroergotamine—Rash—Topiramate—obesity	6.95e-05	0.000437	CcSEcCtD
Dihydroergotamine—Dermatitis—Topiramate—obesity	6.95e-05	0.000437	CcSEcCtD
Dihydroergotamine—Headache—Topiramate—obesity	6.91e-05	0.000435	CcSEcCtD
Dihydroergotamine—Nausea—Topiramate—obesity	6.55e-05	0.000412	CcSEcCtD
Dihydroergotamine—ADRA2A—Hemostasis—PIK3CA—obesity	4.26e-06	3.5e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CYCS—obesity	4.25e-06	3.5e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—PIK3CA—obesity	4.23e-06	3.47e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—SERPINE1—obesity	4.22e-06	3.47e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—LPIN1—obesity	4.21e-06	3.46e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—PIK3CA—obesity	4.2e-06	3.46e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—AGT—obesity	4.18e-06	3.44e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CCL5—obesity	4.18e-06	3.44e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—GOT1—obesity	4.17e-06	3.43e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—GGT1—obesity	4.17e-06	3.43e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—PIK3CA—obesity	4.17e-06	3.43e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—ESR1—obesity	4.16e-06	3.42e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—APOA5—obesity	4.12e-06	3.39e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—F2—obesity	4.11e-06	3.38e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PRKCB—obesity	4.11e-06	3.38e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—NCOA1—obesity	4.11e-06	3.38e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—TYK2—obesity	4.1e-06	3.37e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—APOE—obesity	4.1e-06	3.37e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—LPL—obesity	4.09e-06	3.36e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—PIK3CA—obesity	4.09e-06	3.36e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—PIK3CB—obesity	4.07e-06	3.35e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—MTOR—obesity	4.07e-06	3.35e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—RHOA—obesity	4.07e-06	3.35e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—BAD—obesity	4.06e-06	3.34e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—CAV1—obesity	4.06e-06	3.34e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—FOXO1—obesity	4.06e-06	3.34e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—RPS6KB1—obesity	4.05e-06	3.33e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—APOA1—obesity	4.05e-06	3.33e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—STK11—obesity	4.05e-06	3.33e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CYP19A1—obesity	4.05e-06	3.33e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—MTOR—obesity	4.04e-06	3.32e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—PIK3CB—obesity	4.04e-06	3.32e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—NOS3—obesity	4.03e-06	3.31e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—PIK3R1—obesity	4.03e-06	3.31e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—PIK3CB—obesity	4.01e-06	3.3e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—MTOR—obesity	3.96e-06	3.25e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—PIK3CB—obesity	3.96e-06	3.25e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PIK3CG—obesity	3.94e-06	3.24e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—SLC22A1—obesity	3.93e-06	3.23e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CLOCK—obesity	3.93e-06	3.23e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IRS1—obesity	3.89e-06	3.2e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—PIK3CA—obesity	3.84e-06	3.15e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—SULT2A1—obesity	3.83e-06	3.15e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GLP1R—obesity	3.83e-06	3.15e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—AKT1—obesity	3.78e-06	3.11e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—DPYD—obesity	3.77e-06	3.1e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PRKCD—obesity	3.77e-06	3.1e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—COMT—obesity	3.77e-06	3.1e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—AKT1—obesity	3.75e-06	3.09e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—POMC—obesity	3.75e-06	3.08e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—INS—obesity	3.73e-06	3.06e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—IL6—obesity	3.72e-06	3.06e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—MTOR—obesity	3.72e-06	3.06e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—PIK3CB—obesity	3.72e-06	3.06e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PPARGC1A—obesity	3.71e-06	3.05e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—GNB3—obesity	3.71e-06	3.05e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PIK3CG—obesity	3.7e-06	3.04e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—HMOX1—obesity	3.7e-06	3.04e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—IL6—obesity	3.69e-06	3.04e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—HTR2A—obesity	3.69e-06	3.03e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—C3—obesity	3.68e-06	3.03e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—AKT1—obesity	3.68e-06	3.02e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CCL2—obesity	3.67e-06	3.01e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PRKAR2B—obesity	3.63e-06	2.98e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—IL6—obesity	3.62e-06	2.97e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—GNAS—obesity	3.62e-06	2.97e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IGF1—obesity	3.6e-06	2.96e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—DCN—obesity	3.6e-06	2.96e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—AKT2—obesity	3.6e-06	2.96e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PPARG—obesity	3.57e-06	2.94e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—APOB—obesity	3.54e-06	2.91e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—MMP9—obesity	3.54e-06	2.91e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—POMC—obesity	3.52e-06	2.89e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—MMP9—obesity	3.51e-06	2.89e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CPT1A—obesity	3.5e-06	2.88e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IRS2—obesity	3.5e-06	2.88e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—INS—obesity	3.5e-06	2.88e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—AGT—obesity	3.5e-06	2.88e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—AKT1—obesity	3.48e-06	2.86e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PIK3CD—obesity	3.46e-06	2.84e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—AKT1—obesity	3.45e-06	2.84e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—MAPK8—obesity	3.44e-06	2.83e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—MMP9—obesity	3.44e-06	2.83e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—NAMPT—obesity	3.44e-06	2.82e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—AKT1—obesity	3.43e-06	2.82e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—LEP—obesity	3.43e-06	2.82e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—APOE—obesity	3.43e-06	2.82e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—PIK3CA—obesity	3.43e-06	2.82e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—SERPINE1—obesity	3.42e-06	2.81e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—MAPK8—obesity	3.42e-06	2.81e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—LIPC—obesity	3.41e-06	2.81e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GCK—obesity	3.41e-06	2.81e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—AKT1—obesity	3.41e-06	2.8e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—IL6—obesity	3.4e-06	2.79e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CAV1—obesity	3.4e-06	2.79e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—APOC3—obesity	3.39e-06	2.79e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—APOA1—obesity	3.39e-06	2.79e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—LPL—obesity	3.38e-06	2.78e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—MAPK8—obesity	3.35e-06	2.75e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—AKT1—obesity	3.34e-06	2.74e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—TYK2—obesity	3.33e-06	2.74e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—RHOA—obesity	3.3e-06	2.71e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—GPX1—obesity	3.3e-06	2.71e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CETP—obesity	3.29e-06	2.71e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—ESR1—obesity	3.27e-06	2.69e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—NOS3—obesity	3.27e-06	2.69e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PIK3R1—obesity	3.27e-06	2.69e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—SDC1—obesity	3.26e-06	2.68e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PIK3CD—obesity	3.25e-06	2.67e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PRKCB—obesity	3.23e-06	2.66e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—MMP9—obesity	3.23e-06	2.66e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—F2—obesity	3.23e-06	2.66e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CD36—obesity	3.21e-06	2.64e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—ALB—obesity	3.21e-06	2.64e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—AKR1C3—obesity	3.2e-06	2.63e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—BAD—obesity	3.19e-06	2.63e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—SCARB1—obesity	3.15e-06	2.59e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—STAT3—obesity	3.15e-06	2.59e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—MAPK8—obesity	3.14e-06	2.58e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—AKT1—obesity	3.14e-06	2.58e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—STAT3—obesity	3.12e-06	2.57e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—PIK3CA—obesity	3.11e-06	2.56e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PIK3CG—obesity	3.09e-06	2.54e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—NOS3—obesity	3.07e-06	2.52e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PIK3R1—obesity	3.07e-06	2.52e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—SREBF1—obesity	3.06e-06	2.52e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—STAT3—obesity	3.06e-06	2.51e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IRS1—obesity	3.06e-06	2.51e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—MTHFR—obesity	3.04e-06	2.5e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PIK3CB—obesity	3.02e-06	2.48e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MTOR—obesity	3.02e-06	2.48e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PPARA—obesity	2.99e-06	2.46e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GOT2—obesity	2.98e-06	2.45e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—POMC—obesity	2.94e-06	2.42e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—INS—obesity	2.93e-06	2.41e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—MYC—obesity	2.93e-06	2.4e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—TGFB1—obesity	2.92e-06	2.4e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—FASN—obesity	2.92e-06	2.4e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—MYC—obesity	2.9e-06	2.39e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—BCHE—obesity	2.9e-06	2.39e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—TGFB1—obesity	2.9e-06	2.38e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—AGT—obesity	2.89e-06	2.38e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CCL2—obesity	2.88e-06	2.37e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—STAT3—obesity	2.87e-06	2.36e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—MYC—obesity	2.84e-06	2.34e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—TGFB1—obesity	2.84e-06	2.33e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PIK3CB—obesity	2.83e-06	2.33e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—APOE—obesity	2.83e-06	2.33e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IGF1—obesity	2.83e-06	2.33e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—AKT2—obesity	2.83e-06	2.33e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PTGS2—obesity	2.81e-06	2.31e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CAV1—obesity	2.81e-06	2.31e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—APOA1—obesity	2.8e-06	2.3e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CYP2E1—obesity	2.8e-06	2.3e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—AKT1—obesity	2.8e-06	2.3e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—NQO1—obesity	2.77e-06	2.28e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—IL6—obesity	2.76e-06	2.27e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PIK3CD—obesity	2.72e-06	2.24e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—PIK3CA—obesity	2.69e-06	2.21e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—SERPINE1—obesity	2.69e-06	2.21e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—MYC—obesity	2.67e-06	2.2e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—TGFB1—obesity	2.66e-06	2.19e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GCG—obesity	2.66e-06	2.18e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—SLC2A4—obesity	2.66e-06	2.18e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MMP9—obesity	2.62e-06	2.15e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CYCS—obesity	2.62e-06	2.15e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TYK2—obesity	2.62e-06	2.15e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—RHOA—obesity	2.59e-06	2.13e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GOT1—obesity	2.57e-06	2.11e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GGT1—obesity	2.57e-06	2.11e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—NOS3—obesity	2.57e-06	2.11e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PIK3R1—obesity	2.57e-06	2.11e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PIK3CG—obesity	2.56e-06	2.1e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MAPK8—obesity	2.55e-06	2.1e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—AKT1—obesity	2.54e-06	2.09e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—NCOA1—obesity	2.53e-06	2.08e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—STK11—obesity	2.5e-06	2.05e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CYP19A1—obesity	2.5e-06	2.05e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—PIK3CA—obesity	2.48e-06	2.04e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PPARG—obesity	2.47e-06	2.03e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—PIK3CA—obesity	2.46e-06	2.03e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—PIK3CA—obesity	2.45e-06	2.01e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—POMC—obesity	2.44e-06	2e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—INS—obesity	2.42e-06	1.99e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—PIK3CA—obesity	2.41e-06	1.98e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MTOR—obesity	2.37e-06	1.95e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PIK3CB—obesity	2.37e-06	1.95e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—STAT3—obesity	2.33e-06	1.92e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—COMT—obesity	2.32e-06	1.91e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GNB3—obesity	2.29e-06	1.88e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PPARGC1A—obesity	2.29e-06	1.88e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—HMOX1—obesity	2.28e-06	1.87e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—PIK3CA—obesity	2.27e-06	1.86e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PIK3CD—obesity	2.25e-06	1.85e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GNAS—obesity	2.23e-06	1.83e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—ALB—obesity	2.22e-06	1.82e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—AKT1—obesity	2.2e-06	1.81e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—IL6—obesity	2.2e-06	1.81e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—IL6—obesity	2.18e-06	1.79e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—APOB—obesity	2.18e-06	1.79e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—IL6—obesity	2.17e-06	1.78e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MYC—obesity	2.17e-06	1.78e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—TGFB1—obesity	2.16e-06	1.78e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—IL6—obesity	2.14e-06	1.76e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PIK3R1—obesity	2.12e-06	1.75e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—NOS3—obesity	2.12e-06	1.75e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—LPL—obesity	2.08e-06	1.71e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MMP9—obesity	2.06e-06	1.69e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GPX1—obesity	2.03e-06	1.67e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—AKT1—obesity	2.03e-06	1.67e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—AKT1—obesity	2.01e-06	1.66e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—IL6—obesity	2.01e-06	1.65e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MAPK8—obesity	2e-06	1.65e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—AKT1—obesity	2e-06	1.64e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CD36—obesity	1.98e-06	1.63e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—AKT1—obesity	1.97e-06	1.62e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PIK3CB—obesity	1.96e-06	1.61e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PTGS2—obesity	1.94e-06	1.6e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—MTHFR—obesity	1.88e-06	1.54e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—AKT1—obesity	1.85e-06	1.52e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PPARA—obesity	1.84e-06	1.51e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PIK3CA—obesity	1.84e-06	1.51e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—STAT3—obesity	1.83e-06	1.51e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—AGT—obesity	1.78e-06	1.47e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—APOE—obesity	1.75e-06	1.44e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CAV1—obesity	1.73e-06	1.42e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PIK3CA—obesity	1.73e-06	1.42e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—APOA1—obesity	1.73e-06	1.42e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MYC—obesity	1.7e-06	1.4e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TGFB1—obesity	1.7e-06	1.4e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IL6—obesity	1.63e-06	1.34e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PIK3CG—obesity	1.58e-06	1.3e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PPARG—obesity	1.52e-06	1.25e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—AKT1—obesity	1.5e-06	1.23e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—POMC—obesity	1.5e-06	1.23e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—INS—obesity	1.49e-06	1.23e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PIK3CA—obesity	1.45e-06	1.19e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—AKT1—obesity	1.41e-06	1.16e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PIK3CD—obesity	1.39e-06	1.14e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ALB—obesity	1.37e-06	1.12e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—NOS3—obesity	1.31e-06	1.08e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PIK3R1—obesity	1.31e-06	1.08e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IL6—obesity	1.28e-06	1.05e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PIK3CB—obesity	1.21e-06	9.93e-06	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PTGS2—obesity	1.2e-06	9.84e-06	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PIK3CA—obesity	1.19e-06	9.82e-06	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—AKT1—obesity	1.18e-06	9.7e-06	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—AKT1—obesity	9.76e-07	8.02e-06	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PIK3CA—obesity	7.36e-07	6.05e-06	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—AKT1—obesity	6.01e-07	4.94e-06	CbGpPWpGaD
